With the increase in the number of novel drugs for inflammatory bowel disease (IBD),
comparing therapeutic options or strategies has become a key challenge in IBD trials. Head …

Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis
(UC), are lifelong diseases characterized by chronic inflammation of the gastrointestinal tract …

Background Direct comparisons are lacking between vedolizumab and tumour necrosis
factor (TNF)‐antagonist therapy in Crohn's disease (CD). Aim To compare safety and …

Objectives: Inflammatory bowel disease (IBD) can be successfully treated with vedolizumab.
Studies in adult IBD patients have shown that differences in response to vedolizumab may …

METHODS: Clinical information was ascertained from electronic medical records of patients
enrolled in TARGET-IBD, a prospective longitudinal observational cohort of patients with …

Background Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs)
revolutionized the management of ulcerative colitis (UC). This study assessed the …

To the editors, Evidence is accumulating about the real-world effectiveness of vedolizumab
(VDZ) for the treatment of inflammatory bowel diseases (IBD). 1, 2 Furthermore, the clinical …

Introduction Adalimumab and golimumab are subcutaneously administered anti-tumor
necrosis factor α (TNFα) biologics used in the treatment of ulcerative colitis (UC). To date, no …

Background. Vedolizumab is a gut‐selective monoclonal anti‐α4β7‐integrin antibody
approved for the treatment of adults with moderately to severely active Crohn's disease …

Successful treatment of steroid‐refractory gastrointestinal acute graft‐versus‐host disease
with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient …